loading...

Denise Golgher

Denise Golgher

生物技术专家 博士

denise.golgher@lickslegal.com

+55 21 3550 3758

Denise Golgher 于 2015 年加入 Licks 律师事务所的里约热内卢办公室,担任生物技术专家。她在细胞生物学、免疫学和生物技术方面拥有 20 多年的工作经验,包括研究和分析人类健康和商业发展方面的新兴技术。此外,Golgher 女士精通巴西的生物技术领域,曾在 2007 年协调过一项研究,并在 2011 年的巴西生物技术地图项目中担任顾问。自 2003 年以来,她为巴西的公司、学者和风险投资家提供咨询,在国外从事生物技术业务。Denise 在FDC(巴西)学习商业管理,该基金会被评为拉丁美洲最好的商学院。 

语言
  • 葡萄牙语
  • 英语
擅长领域
  • 专利
  • 生命科学
个人荣誉(部分)
  • Golgher, D, Rodrigues R, Olmos M and Castro AC. 2018. Breaking through asphalt. The private sector takes the lead in biomedical innovation in Brazil. https://bioengineeringcommunity.nature.com/ users/2889-brady-huggett/posts/40607-breaking-through-asphalt;
  • Torres-Freire, C; Callil, V, Golgher, D. 2015. Human Health Biotechnology in Brazil: Can we advance? Journal of Commercial Biotechnology. 21:20-30;
教育与研究背景
  • Post-doctoral Degree in Tumour Immunology, University of Oxford(laboratory later relocated to Southampton), 2003;
  • PhD in Cell Biology, Johns Hopkins University, 1999;
  • MSc in Biochemistry, University of Sao Paulo (USP), 1992;
  • BSc in Biology, Federal University of Minas Gerais (UFMG), 1989.
近期出版
  • Golgher D.; Rodrigues, R . The Business of Immuno-Oncology;
  • Genetic Engineering and Biotechnology News, 01 fev. 2016;
  • Golgher D Rodrigues R and Massafera RC Biosimilars in Brazil: Developments in 2015 and Business Perspectives Journal of Commercial Biotechnology (2015) 21(4), 44–50;
  • Torres-Freire,C; Callil, V, Golgher,D. 2015. Human Health Biotechnology in Brazil: Can we advance? Journal of Commercial Biotechnology.21:20-30;
  • Zalcberg I and Golgher D. 2015 Molecular Genetics of Glioblastomas: Defining sub-types and understanding biology. Neuroimaging Clin N Am. 25(1):97-103;
  • Golgher D, Elliott, T, Howarth, M. 2003. Processing and presentation of glycoproteins in the MHC class I and II antigen presentation pathways In: Immunobiology of Carbohydrates ed.: Landes Bioscience;
  • Golgher D, Jones E, Powrie F, Elliott T, Gallimore A. 2002. Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur J Immunol. 32(11):3267-75;
  • Golgher D, Korangy F, Gao B, Gorski K, Jaffee E, Edidin M,; Pardoll DM, Elliott T. 2001. Animmunodominant MHC class II-restricted tumor antigen is conformation dependent and binds to the endoplasmic reticulum chaperone, calreticulin. J Immunol. 167(1):147-55.